Advertisement
ProteinSimple
ProteinSimple

The Scientist

» pharmaceuticals

Most Recent

image: Abbott Acquires Diagnostics Firm

Abbott Acquires Diagnostics Firm

By | February 2, 2016

In a deal worth $5.8 billion, Abbott Laboratories is buying medical test–maker Alere.

0 Comments

image: Shire to Buy Baxalta for $32 Billion

Shire to Buy Baxalta for $32 Billion

By | January 12, 2016

The Dublin-based pharma giant is set to acquire Baxalta, an Illinois-based Baxter spinoff, expanding its rare disease drug portfolio.

0 Comments

image: Thermo Fisher to Acquire Affymetrix

Thermo Fisher to Acquire Affymetrix

By | January 11, 2016

The boards of both companies have agreed to a $1.3 billion deal, which is subject to Affymetrix shareholder approval.

0 Comments

image: Bayer Enters CRISPR Field

Bayer Enters CRISPR Field

By | December 22, 2015

The pharmaceutical company will spend $335 million on a new venture with biotech startup CRISPR Therapeutics.

0 Comments

image: First Dengue Vax Approved

First Dengue Vax Approved

By | December 11, 2015

Mexico’s health ministry has OKed the vaccine for people between nine and 45 years old.

0 Comments

image: Daraprim Discounts Offered

Daraprim Discounts Offered

By | November 26, 2015

Turing Pharmaceuticals will soon offer discounts to hospitals for its toxoplasmosis-fighting drug, the company announced, but some say the proposed price reductions are not enough.

0 Comments

image: Pfizer and Allergan to Merge

Pfizer and Allergan to Merge

By | November 23, 2015

The two drugmakers will join forces in a $160 billion deal—if it’s given the regulatory green light.

0 Comments

image: Daraprim Alternative

Daraprim Alternative

By | October 22, 2015

A specialty pharmaceuticals company announces plans to produce a toxoplasmosis drug containing the same active ingredient as the pill at the center of an ongoing drug-pricing controversy.

1 Comment

image: Teva Buys Mexican Pharma Firm

Teva Buys Mexican Pharma Firm

By | October 5, 2015

The Israeli drugmaker is purchasing the pharmaceutical company Rimsa for $2.3 billion.

0 Comments

image: Biotech Stocks Take a Hit

Biotech Stocks Take a Hit

By | September 30, 2015

Some say the biotech bubble has burst over concerns that drug prices are too high—and may soon be regulated.

1 Comment

Advertisement
EMD Millipore
EMD Millipore

Popular Now

  1. The Mycobiome
    Features The Mycobiome

    The largely overlooked resident fungal community plays a critical role in human health and disease.

  2. Antibody Alternatives
    Features Antibody Alternatives

    Nucleic acid aptamers and protein scaffolds could change the way researchers study biological processes and treat disease.

  3. Holding Their Ground
    Features Holding Their Ground

    To protect the global food supply, scientists want to understand—and enhance—plants’ natural resistance to pathogens.

  4. Circadian Clock and Aging
    Daily News Circadian Clock and Aging

    Whether a critical circadian clock gene is deleted before or after birth impacts the observed aging-related effects in mice.

Advertisement
Lexogen
Lexogen
Advertisement
Life Technologies